This study investigates changes in the immune microenvironment during GIST progression and identifies MYBL1 and AIF1L as key mediators regulating CD8<sup>+</sup> T cell function and PD-1 response, providing new strategies for combined immunotherapy in GIST. This evidence concerns the gene AIF1L and gastrointestinal stromal tumor.